SLRN - Pliant Therapeutics: An Activist On Deck
2025-04-03 12:22:51 ET
Summary
- Pliant Therapeutics suffered a major setback with its lead drug candidate, causing its stock to plummet well below its cash value.
- Activist investor Kevin Tang has acquired a significant stake in PLRX, aiming to capitalize on the company's large cash reserves.
- Tang's history of acquiring biotechs at a discount suggests a potential profitable takeover of PLRX, despite management's defensive "poison pill" strategy.
- The substantial gap between PLRX's current share price and its cash balance presents a compelling investment opportunity, with Tang likely to make an acquisition offer soon.
...
Pliant Therapeutics: An Activist On Deck